FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesGCSG 2019 US Conference: Presentation and Workshop Slides
Topic: Conference
Presentation
Members
Current Challenges in Cell and Gene Therapy
Topic: Regulatory
Webinar
Free
Industry Evolution – A Vision of the Clinical Supply Chain in the Next Decade
Topic: Supply Chain
White Paper
Free
